The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension

The BREELIB nebulizer was developed for iloprost to reduce inhalation times for patients with pulmonary arterial hypertension (PAH). This multicenter, randomized, unblinded, four-part study compared inhalation time, pharmacokinetics, and acute tolerability of iloprost 5 µg at mouthpiece delivered vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gessler, Tobias, Ghofrani, Hossein-Ardeschir, Held, Matthias, Klose, Hans, Leuchte, Hanno, Olschewski, Horst, Rosenkranz, Stephan, Fels, Lueder, Li, Na, Ren, Dawn, Kaiser, Andreas, Schultze-Mosgau, Marcus-Hillert, Müllinger, Bernhard, Rohde, Beate, Seeger, Werner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467944/
https://www.ncbi.nlm.nih.gov/pubmed/28597762
http://dx.doi.org/10.1177/2045893217706691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467944/
https://www.ncbi.nlm.nih.gov/pubmed/28597762
http://dx.doi.org/10.1177/2045893217706691

Ejemplares similares